474255-10-2
474255-10-2
Chemical Structure
MM0299
- CAS No.: 474255-10-2
- Formula:C26H23NO5
- Molecular Weight:429.46
InChIKey: SYUJAWVNBGZCNK-WXRIWDPGSA-N
SMILES: O=C(N1C(C=C2)=CC=C2OCC(C(C=C3)=CC=C3OC)=O)C4C(C1=O)[C@@H]5[C@@H]6C(C6)[C@H]4C=C5
Biological Activity: MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC50 value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MM0299 | 98.51% | MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC50 value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
exo-IWR-1 (Standard) | ≥98% | exo-IWR-1 (Standard) is the analytical standard of exo-IWR-1 (HY-108437). This product is intended for research and analytical applications. exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IWR-1 | 99.60% | IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DCZ0415 | 99.81% | DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MEIS-IN-2 | 99.33% | MEIS-IN-2 is a myeloid ecotropic viral integration site 1 (MEIS1) inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MEIS-IN-3 | MEIS-IN-3 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
S-2E | S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
COX-2-IN-13 | COX-2-IN-13 (compound 13e) is a potent and selective inhibitor of COX-2 with an IC50 of 0.98 μM. COX-2-IN-13 is an anti-inflammatory agent. COX-2-IN-13 shows safety in-vivo acute toxicity study. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
mGluR7-IN-1 | mGluR7-IN-1 (compound 2Z) is a mGluR3 inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Apoptosis inducer 19 | 98.31% | Apoptosis inducer 19 (Compound 7g) is an Apoptosis inducer. Apoptosis inducer 19 elevates expression of pro-apoptotic proteins (Bax and caspase-3) and downregulates anti-apoptotic protein (Bcl-2). Apoptosis inducer 19 upregulates cellular reactive oxygen species (ROS) levels and disrupts mitochondrial membrane potential (MMP). Apoptosis inducer 19 can be used for triple-negative breast cancer (TNBC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TI17 | 95.97% | TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity. TI17 effectively inhibits multiple myeloma (MM) cell proliferation and induces cell cycle arrest and apoptosis. Trip13 is an AAA-ATPase that mediates double-strand break (DSB) repair; TI17 inhibits Trip13 function and increases DNA damage. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
